Načítá se...
Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
Background and Objective: Radium-223 dichloride (Xofigo(®)) is a calcium mimetic agent approved for the treatment of castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease. This targeted, α-particle-emitting therapy has demonstrated si...
Uloženo v:
| Vydáno v: | Medicina (Kaunas) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572036/ https://ncbi.nlm.nih.gov/pubmed/31100964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55050149 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|